Cargando…
TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer
Background: TRIM37 (Tripartite Motif Containing 37) is an E3 ubiquitin ligase for histone H2A and inhibits transcription in several genes. However, it is not known whether it plays a role in gastric cancer (GC). In this study, we tested whether TRIM37 acts as a cancer-promoting factor by being overe...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739001/ https://www.ncbi.nlm.nih.gov/pubmed/33391428 http://dx.doi.org/10.7150/jca.47577 |
_version_ | 1783623240681259008 |
---|---|
author | Nishibeppu, Keiji Komatsu, Shuhei Kiuchi, Jun Kishimoto, Takuma Takashima, Yusuke Shoda, Katsutoshi Arita, Tomohiro Kosuga, Toshiyuki Konishi, Hirotaka Shiozaki, Atsushi Kubota, Takeshi Okamoto, Kazuma Fujiwara, Hitoshi Tsuda, Hitoshi Otsuji, Eigo |
author_facet | Nishibeppu, Keiji Komatsu, Shuhei Kiuchi, Jun Kishimoto, Takuma Takashima, Yusuke Shoda, Katsutoshi Arita, Tomohiro Kosuga, Toshiyuki Konishi, Hirotaka Shiozaki, Atsushi Kubota, Takeshi Okamoto, Kazuma Fujiwara, Hitoshi Tsuda, Hitoshi Otsuji, Eigo |
author_sort | Nishibeppu, Keiji |
collection | PubMed |
description | Background: TRIM37 (Tripartite Motif Containing 37) is an E3 ubiquitin ligase for histone H2A and inhibits transcription in several genes. However, it is not known whether it plays a role in gastric cancer (GC). In this study, we tested whether TRIM37 acts as a cancer-promoting factor by being overexpressed in GC. Methods: We analyzed GC cell lines and 124 primary tumors, which were curatively resected in our hospital between 2001 and 2003. Results: Overexpression of the TRIM37 protein was detected in almost all GC cell lines and GC samples (76 out of 124 cases) and was significantly correlated with lymphatic and venous invasion, advanced T-Stage, N-Stage, histology and high recurrence rate. Patients with TRIM37 overexpressing tumors had a worse survival rate than those with non-expressing tumors (P=0.0057). Moreover, TRIM37 positivity was identified as an independent factor predicting worse outcomes (P=0.018, Hazard ratio 3.41). The apoptotic cell analysis showed that the knockdown of TRIM37 increased apoptosis in comparison with the control. In TRIM37 overexpressing GC cells, knockdown of TRIM37 suppressed the migration and invasion. Conclusions: TRIM37 plays a crucial role in tumor malignant potential through its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in GC. |
format | Online Article Text |
id | pubmed-7739001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-77390012021-01-01 TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer Nishibeppu, Keiji Komatsu, Shuhei Kiuchi, Jun Kishimoto, Takuma Takashima, Yusuke Shoda, Katsutoshi Arita, Tomohiro Kosuga, Toshiyuki Konishi, Hirotaka Shiozaki, Atsushi Kubota, Takeshi Okamoto, Kazuma Fujiwara, Hitoshi Tsuda, Hitoshi Otsuji, Eigo J Cancer Research Paper Background: TRIM37 (Tripartite Motif Containing 37) is an E3 ubiquitin ligase for histone H2A and inhibits transcription in several genes. However, it is not known whether it plays a role in gastric cancer (GC). In this study, we tested whether TRIM37 acts as a cancer-promoting factor by being overexpressed in GC. Methods: We analyzed GC cell lines and 124 primary tumors, which were curatively resected in our hospital between 2001 and 2003. Results: Overexpression of the TRIM37 protein was detected in almost all GC cell lines and GC samples (76 out of 124 cases) and was significantly correlated with lymphatic and venous invasion, advanced T-Stage, N-Stage, histology and high recurrence rate. Patients with TRIM37 overexpressing tumors had a worse survival rate than those with non-expressing tumors (P=0.0057). Moreover, TRIM37 positivity was identified as an independent factor predicting worse outcomes (P=0.018, Hazard ratio 3.41). The apoptotic cell analysis showed that the knockdown of TRIM37 increased apoptosis in comparison with the control. In TRIM37 overexpressing GC cells, knockdown of TRIM37 suppressed the migration and invasion. Conclusions: TRIM37 plays a crucial role in tumor malignant potential through its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in GC. Ivyspring International Publisher 2021-01-01 /pmc/articles/PMC7739001/ /pubmed/33391428 http://dx.doi.org/10.7150/jca.47577 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Nishibeppu, Keiji Komatsu, Shuhei Kiuchi, Jun Kishimoto, Takuma Takashima, Yusuke Shoda, Katsutoshi Arita, Tomohiro Kosuga, Toshiyuki Konishi, Hirotaka Shiozaki, Atsushi Kubota, Takeshi Okamoto, Kazuma Fujiwara, Hitoshi Tsuda, Hitoshi Otsuji, Eigo TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer |
title | TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer |
title_full | TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer |
title_fullStr | TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer |
title_full_unstemmed | TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer |
title_short | TRIM37 contributes to malignant outcomes and CDDP resistance in gastric cancer |
title_sort | trim37 contributes to malignant outcomes and cddp resistance in gastric cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739001/ https://www.ncbi.nlm.nih.gov/pubmed/33391428 http://dx.doi.org/10.7150/jca.47577 |
work_keys_str_mv | AT nishibeppukeiji trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT komatsushuhei trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT kiuchijun trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT kishimototakuma trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT takashimayusuke trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT shodakatsutoshi trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT aritatomohiro trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT kosugatoshiyuki trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT konishihirotaka trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT shiozakiatsushi trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT kubotatakeshi trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT okamotokazuma trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT fujiwarahitoshi trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT tsudahitoshi trim37contributestomalignantoutcomesandcddpresistanceingastriccancer AT otsujieigo trim37contributestomalignantoutcomesandcddpresistanceingastriccancer |